Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials
Yang, Fang , Molina, Julian R. , Hálfdánarson, Þorvarður R. , Pagliaro, Lance C. , Li, Rutian , Wang, Lifeng , Liu, Baorui , Nowakowski, Grzegorz S. , Wang, Michael , Halfdanarson, Thorvardur R , Markovic, Svetomir N. , Chintakuntlawar, Ashish V. , Wei, Jia , Wang, Yucai

Mayo Clinic

JAMA Network Open | August 7, 2020 | Volume: 3 | Issue: 8 | Pages: e2012534

10.1001/jamanetworkopen.2020.12534 | PMID 32766800 Get It

Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology
Nudelman, Kelly , Allen, Mariet , Hodges, Angela , Kim, Sungeun , Risacher, Shannon L. , Apostolova, Liana G. , Lin, Kuang, Lunnon, Katie , Wang, Xue , Burgess, Jeremy D. , Ertekin‐Taner, Nilüfer , Petersen, Ronald C. , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley , Lovestone, Simon , Simmons, Andrew , Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Nudelman, Kelly N , Nho, Kwangsik T. , Neuhaus, Isaac, Foroud, Tatiana , Saykin, Andrew J. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | August 5, 2020 | Volume: 16 | Issue: 9 | Pages: 1213-1223

10.1002/alz.12092 | PMID 32755048 Get It

AbstractIntroductionAbnormal gene expression patterns may contribute to the onset and progression of late‐onset Alzheimer's disease (LOAD).MethodsWe performed transcriptome‐wide meta‐analysis (N = 1440) of blood‐based microarray gene expression profiles as well as neuroimaging and cerebrospinal fluid (CSF) endophenotype analysis.ResultsWe identified and replicated five genes (CREB5, CD46, TMBIM6, IRAK3, and RPAIN) as significantly dysregulated in LOAD. The most significantly altered gene, CREB5, was also associated with brain atrophy and increased amyloid beta (Aβ) accumulation, especially in the entorhinal cortex region. cis‐expression quantitative trait loci mapping analysis of CREB5 detected five significant associations (P < 5 × 10−8), where rs56388170 (most significant) was also significantly associated with global cortical Aβ deposition measured by [18F]Florbetapir positron emission tomography and CSF Aβ1‐42.DiscussionRNA from peripheral blood indicated a differential gene expression pattern in LOAD. Genes identified have been implicated in biological processes relevant to Alzheimer's disease. CREB, in particular, plays a key role in nervous system development, cell survival, plasticity, and learning and memory.
Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci
Yan, Huihuang , Tian, Shulan , Kleinstern, Geffen , Wang, Zhiquan , Lee, Jeong‐Heon , Cerhan, James R. , Braggio, Esteban , Boddicker, Nicholas J, Cerhan, James R , Lee, Jeong-Heon , Braggio, Esteban , Boddicker, Nicholas , Kay, Neil E. , Slager, Susan L. , Wang, Zhiquan

Mayo Clinic

Human Molecular Genetics | August 3, 2020 | Volume: 29 | Issue: 16 | Pages: 2761-2774

10.1093/hmg/ddaa165 | PMID 32744316 Get It

Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. It has a strong genetic basis, showing a ~ 8-fold increased risk of CLL in first-degree relatives. Genome-wide association studies (GWAS) have identified 41 risk variants across 41 loci. However, for a majority of the loci, the functional variants and the mechanisms underlying their causal roles remain undefined. Here, we examined the genetic and epigenetic features associated with 12 index variants, along with any correlated (r2 ≥ 0.5) variants, at the CLL risk loci located outside of gene promoters. Based on publicly available ChIP-seq and chromatin accessibility data as well as our own ChIP-seq data from CLL patients, we identified six candidate functional variants at six loci and at least two candidate functional variants at each of the remaining six loci. The functional variants are predominantly located within enhancers or super-enhancers, including bi-directionally transcribed enhancers, which are often restricted to immune cell types. Furthermore, we found that, at 78% of the functional variants, the alternative alleles altered the transcription factor binding motifs or histone modifications, indicating the involvement of these variants in the change of local chromatin state. Finally, the enhancers carrying functional variants physically interacted with genes enriched in the type I interferon signaling pathway, apoptosis, or TP53 network that are known to play key roles in CLL. These results support the regulatory roles for inherited noncoding variants in the pathogenesis of CLL.
Subphenotyping depression using machine learning and electronic health records
Xu, Zhenxing , Adekkanattu, Prakash , Bose, Budhaditya, Vekaria, Veer , Brandt, Pascal , Jiang, Guoqian, Kiefer, Richard C. , Luo, Yuan , Pathak, Jyotishman , Vekaria, Veer , Brandt, Pascal S , Xu, Jie , Luo, Yuan , Wang, Fei , Jiang, Guoqian , Pacheco, Jennifer A. , Rasmussen, Luke V. , Xu, Jie , Alexopoulos, George S.

Mayo Clinic

Learning Health Systems | August 3, 2020 | Volume: 4 | Issue: 4 | Pages: No page available

10.1002/lrh2.10241 | PMID 33083540 Get It

AbstractObjectiveTo identify depression subphenotypes from Electronic Health Records (EHRs) using machine learning methods, and analyze their characteristics with respect to patient demographics, comorbidities, and medications.Materials and MethodsUsing EHRs from the INSIGHT Clinical Research Network (CRN) database, multiple machine learning (ML) algorithms were applied to analyze 11 275 patients with depression to discern depression subphenotypes with distinct characteristics.ResultsUsing the computational approaches, we derived three depression subphenotypes: Phenotype_A (n = 2791; 31.35%) included patients who were the oldest (mean (SD) age, 72.55 (14.93) years), had the most comorbidities, and took the most medications. The most common comorbidities in this cluster of patients were hyperlipidemia, hypertension, and diabetes. Phenotype_B (mean (SD) age, 68.44 (19.09) years) was the largest cluster (n = 4687; 52.65%), and included patients suffering from moderate loss of body function. Asthma, fibromyalgia, and Chronic Pain and Fatigue (CPF) were common comorbidities in this subphenotype. Phenotype_C (n = 1452; 16.31%) included patients who were younger (mean (SD) age, 63.47 (18.81) years), had the fewest comorbidities, and took fewer medications. Anxiety and tobacco use were common comorbidities in this subphenotype.ConclusionComputationally deriving depression subtypes can provide meaningful insights and improve understanding of depression as a heterogeneous disorder. Further investigation is needed to assess the utility of these derived phenotypes to inform clinical trial design and interpretation in routine patient care.
Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer
Du, Meijun , Huang, Chiang‐Ching , Tan, Winston , Kohli, Manish , Wang, Liang , Kohli, Manish , Wang, Liang

Mayo Clinic

Cancers | August 3, 2020 | Volume: 12 | Issue: 8 | Pages: 2139

10.3390/cancers12082139 | PMID 32752286 Get It

Amplification of androgen receptor (AR) is a common genomic event in metastatic castration-resistant prostate cancer (mCRPC). To evaluate the prognostic value of the amplifications of specific loci in the AR gene in cell-free DNA, we developed a multiplex digital PCR (dPCR) assay that targeted AR enhancer (AR-En), AR exon 1 (AR-E1), AR exon 8 (AR-E8) and OPHN1 (downstream of AR). We selected three relatively stable genes, C2orf16, FAM111B, and GRIA3, as reference controls for copy number normalization. One hundred and eight mCRPC patients were recruited to test the association of specific AR loci amplification with clinical outcome. Using a normalized ratio ≥ 1.92 as cutoff, amplification of AR-En, AR-E1, AR-E8 and OPHN1 was observed in 28, 25, 24 and 19 of 108 mCRPC patients, respectively. Among the 41 patients with AR region amplification, 9 (21.9%) showed amplification at all four selected regions and 15 (36.6%) showed amplification at AR-En, AR-E1, and AR-E8. Six (14.6%) patients showed independent AR-En amplification, while the remaining 3 (7.3%) demonstrated AR-E8 amplification only. Kaplan–Meier analysis showed overall survival’s association with the amplification of AR-En (p = 0.02, HR = 1.68 (1.07–2.65)), AR-E8 (p = 0.02, HR = 1.78 (1.08–2.92)) and AR-En-E8 (the combination of AR-En and AR-E8 (p = 0.009, HR = 1.77 (1.15–2.73)). Multivariate models that included AR-En-E8 amplification and clinical factors significantly improved prognostic performance (p = 0.0001). With further validation, the multiplex dPCR assay may assist in prognostication of mCRPC patients.
First-Year Results of the American Board of Anesthesiology’s Objective Structured Clinical Examination for Initial Certification
Lien, Cynthia A. , Wang, Ting , Isaak, Robert S. , Peterson-Layne, Cathleen, Harman, Ann E., Macario, Alex, Gaiser, Robert R., Culley, Deborah J. , Keegan, Mark T. , Cole, Daniel J. , Fahy, Brenda G. , Dainer, Rupa J., Warner, David O. , Zhou, Yan , Suresh, Santhanam , Rathmell, James P. , Sun, Huaping

Mayo Clinic

Anesthesia & Analgesia | July 31, 2020 | Volume: 131 | Issue: 5 | Pages: 1412-1418

10.1213/ane.0000000000005086 | PMID 33079864 Get It

In 2018, the American Board of Anesthesiology (ABA) became the first US medical specialty certifying board to incorporate an Objective Structured Clinical Examination (OSCE) into its initial certification examination system. Previously, the ABA’s staged examination system consisted of 2 written examinations (the BASIC and ADVANCED examinations) and the Standardized Oral Examination (SOE). The OSCE and the existing SOE are now 2 separate components of the APPLIED Examination. This report presents the results of the first-year OSCE administration. A total of 1410 candidates took both the OSCE and the SOE in 2018. Candidate performance approximated a normal distribution for both the OSCE and the SOE, and was not associated with the timing of the examination, including day of the week, morning versus afternoon session, and order of the OSCE and the SOE. Practice-based Learning and Improvement was the most difficult station, while Application of Ultrasonography was the least difficult. The correlation coefficient between SOE and OSCE scores was 0.35 ([95% confidence interval {CI}, 0.30–0.39]; P < .001). Scores for the written ADVANCED Examination were modestly correlated with scores for the SOE ( r = 0.29 [95% CI, 0.25–0.34]; P < .001) and the OSCE ( r = 0.15 [95% CI, 0.10–0.20]; P < .001). Most of the candidates who failed the SOE passed the OSCE, and most of the candidates who failed the OSCE passed the SOE. Of the 1410 candidates, 77 (5.5%) failed the OSCE, 155 (11.0%) failed the SOE, and 25 (1.8%) failed both. Thus, 207 (14.7%) failed at least 1 component of the APPLIED Examination. Adding an OSCE to a board certification examination system is feasible. Preliminary evidence indicates that the OSCE measures aspects of candidate abilities distinct from those measured by other examinations used for initial board certification.
Activation of FAK/Rac1/Cdc42‐GTPase signaling ameliorates impaired microglial migration response to Aβ 42 in triggering receptor expressed on myeloid cells 2 loss‐of‐function murine models
Rong, Zhouyi , Cheng, Baoying, Zhong, Li , Jia, Lin , Li, Yanfang , Shue, Francis , Wang, Na , Cheng, Yiyun , Huang, Xiaohua , Liu, Chia‐Chen , Fryer, John Denis , Wang, Xin , Zhang, Yun‐wu , Zheng, Honghua , Liu, Chia-Chen , Shue, Francis , Ye, Xiaowen , Li, Xin , Wang, Na

Mayo Clinic

The FASEB Journal | July 29, 2020 | Volume: 34 | Issue: 8 | Pages: 10984-10997

10.1096/fj.202000550rr | PMID 32613609 Get It

Abstract Mutation of Triggering receptor expressed on myeloid cells 2 (TREM2) impairs the response of microglia to amyloid‐β (Aβ) pathology in Alzheimer's disease (AD), although the mechanism governing TREM2‐regulated microglia recruitment to Aβ plaques remains unresolved. Here, we confirm that TREM2 mutation attenuates microglial migration. Then, using Trem2 −/− mice and an R47H variant mouse model for AD generated for this study, we show that TREM2 deficiency or the AD‐associated R47H mutation results in inhibition of FAK and Rac1/Cdc42‐GTPase signaling critical for cell migration. Intriguingly, treatment with CN04, a Rac1/Cdc42‐GTPase activator, partially enhances microglial migration in response to oligomeric Aβ 42 in Trem2 −/− or R47H microglia both in vitro and in vivo. Our study shows that the dysfunction of microglial migration in the AD‐associated TREM2 R47H variant is caused by FAK/Rac1/Cdc42 signaling disruption, and that activation of this signaling ameliorates impaired microglial migration response to Aβ 42 , suggesting a therapeutic target for R47H‐bearing patients with high risk of AD.
Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults
Diener, Hans‐Christoph, Tassorelli, Cristina , Silberstein, Stephen D. , Ashina, Messoud , Becker, Werner J. , Ferrari, Michel D. , Goadsby, Peter J. , Wang, Shuu‐Jiun , Hoek, Thomas C. van den , Martinelli, Daniele , Silberstein, Stephan D , Goadsby, Peter J , Wang, Shuu-Jiun , Martinelli, Daniele , Ashina, Messoud , Diener, Hans‐Christoph, Dodick, David W. , Lipton, Richard B. , Pozo‐Rosich, Patricia , Houle, Timothy T. , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | July 29, 2020 | Volume: 40 | Issue: 10 | Pages: 1026-1044

10.1177/0333102420941839 | PMID 32722936 Get It

Clinical trials are a key component of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Controlled Trials of Drugs in Migraine. Advances in drugs, devices, and biologicals, as well as novel trial designs, have prompted several updates over the nearly 30 years since, including most recently the Guidelines for controlled trials of preventive treatment of chronic migraine (2018), the Guidelines for controlled trials of acute treatment of migraine attacks in adults (2019), and Guidelines for controlled trials of preventive treatment of migraine in children and adolescents (2019). The present update incorporates findings from new research and is intended to optimize the design of controlled trials of preventive pharmacological treatment of episodic migraine in adults. A guideline for clinical trials with devices will be published separately.
NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
Bano, Shazia , Obaid, Girgis , Swain, Joseph W. R. , Yamada, Marina , Hasan, Tayyaba , Hasan, Tayyaba , Pogue, Brian W. , Wang, Kenneth

Mayo Clinic

Journal of Clinical Medicine | July 27, 2020 | Volume: 9 | Issue: 8 | Pages: 2390

10.3390/jcm9082390 | PMID 32726945 Get It

Receptor heterogeneity in cancer is a major limitation of molecular targeting for cancer therapeutics. Single-receptor-targeted treatment exerts selection pressures that result in treatment escape for low-receptor-expressing tumor subpopulations. To overcome this potential for heterogeneity-driven resistance to molecular targeted photodynamic therapy (PDT), we present for the first time a triple-receptor-targeted photoimmuno-nanoconjugate (TR-PIN) platform. TR-PIN functionalization with cetuximab, holo-transferrin, and trastuzumab conferred specificity for epidermal growth factor receptor (EGFR), transferrin receptor (TfR), and human epidermal growth factor receptor 2 (HER-2), respectively. The TR-PINs exhibited up to a 24-fold improvement in cancer cell binding compared with EGFR-specific cetuximab-targeted PINs (Cet-PINs) in low-EGFR-expressing cell lines. Photodestruction using TR-PINs was significantly higher than the monotargeted Cet-PINs in heterocellular 3D in vitro models of heterogeneous pancreatic ductal adenocarcinoma (PDAC; MIA PaCa-2 cells) and heterogeneous head and neck squamous cell carcinoma (HNSCC, SCC9 cells) containing low-EGFR-expressing T47D (high TfR) or SKOV-3 (high HER-2) cells. Through their capacity for multiple tumor target recognition, TR-PINs can serve as a unique and amenable platform for the effective photodynamic eradication of diverse tumor subpopulations in heterogeneous cancers to mitigate escape for more complete and durable treatment responses.
ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling
Li, Bingjue, Zhu, Chaohong, Dong, Lihua , Xiang, Wenyu, Davidson, Alan J. , Feng, Shi , Wang, Yucheng , Shen, Xiujin , Weng, Chunhua , Teng, Lisha, Wang, Junwen , Chen, Jianghua , Jiang, Hong , Chen, Jianghua , Jiang, Hong , Wang, Junwen , Qin, Jing , Wang, Cuili , Zhu, Tingting, Englert, Christoph

Mayo Clinic

The Journal of Pathology | July 27, 2020 | Volume: 252 | Issue: 3 | Pages: 274-289

10.1002/path.5517 | PMID 32715474 Get It

AbstractDisturbed intrauterine development increases the risk of renal disease. Various studies have reported that Notch signalling plays a significant role in kidney development and kidney diseases. A disintegrin and metalloproteinase domain 10 (ADAM10), an upstream protease of the Notch pathway, is also reportedly involved in renal fibrosis. However, how ADAM10 interacts with the Notch pathway and causes renal fibrosis is not fully understood. In this study, using a prenatal chlorpyrifos (CPF) exposure mouse model, we investigated the role of the ADAM10/Notch axis in kidney development and fibrosis. We found that prenatal CPF‐exposure mice presented overexpression of Adam10, Notch1 and Notch2, and led to premature depletion of Six2+ nephron progenitors and ectopic formation of proximal tubules (PTs) in the embryonic kidney. These abnormal phenotypic changes persisted in mature kidneys due to the continuous activation of ADAM10/Notch and showed aggravated renal fibrosis in adults. Finally, both ADAM10 and NOTCH2 expression were positively correlated with the degree of renal interstitial fibrosis in IgA nephropathy patients, and increased ADAM10 expression was negatively correlated with decreased kidney function evaluated by serum creatinine, cystatin C, and estimated glomerular filtration rate. Regression analysis also indicated that ADAM10 expression was an independent risk factor for fibrosis in IgAN. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.